Yes. Valuation is high currently. Better to buy after listing.
Veeda Clinical Research Files DRHP For Around 1,000 Cr IPO
1. Debt Funding Deal in Progress
Tata Capital is set to extend Rs 60...
Valuation seems agressive as stocks is trading at a much premium rate to the intrinsic valuations.
The consolidated financial results for the quarter ending Dec 31, 2024 (Q3)
The consolidated financial results for the quarter ending Dec 31, 2024 (Q3)
I hv lot of unlisted shares which is listing in recent years 2025…if you interested plz contact us at : 9311506715
Yes available
Financials of Parag Parikh Financial Advisory Services Ltd. (PPFAS) are updated for 2023